Showing 4771-4780 of 7117 results for "".
- Dr. April Armstrong Previews New Era for Oral Psoriasis Treatmentshttps://practicaldermatology.com/news/dr-april-armstrong-previews-new-era-for-oral-psoriasis-treatments/2485362/From wild chickens roaming Maui to a growing flock of groundbreaking psoriasis therapies, April W. Armstrong, MD, MPH, delivered an optimistic update on the future of plaque psoriasis treatment during a presentation at the 2026 Winter Clinical Dermatology Conference in Hawaii. “Psoriasis d
- Vitiligo Linked to Elevated Risk of Herpes Zoster: Cohort Studyhttps://practicaldermatology.com/news/vitiligo-linked-to-elevated-risk-of-herpes-zoster-study-finds/2485328/A new cohort study from Taiwan indicated vitiligo is independently associated with a heightened risk of herpes zoster (HZ), with systemic immunosuppressive therapies compounding the risk further. Using data from Taiwan's Longit
- Systematic Review Suggests Anti-Inflammatory Effects of Astragalus membranaceushttps://practicaldermatology.com/news/systematic-review-shows-anti-inflammatory-effects-of-astragalus-membranaceus/2485129/A new systematic review suggests the traditional botanical Astragalus membranaceus may have clinically relevant anti-aging benefits. "The demand for cosmetic strategies to mitigate [skin ag
- Vixarelimab Shows Dose-Dependent Efficacy in Prurigo Nodularis Phase 2b Trialhttps://practicaldermatology.com/news/vixarelimab-shows-dose-dependent-efficacy-in-prurigo-nodularis-phase-2b-trial/2484982/Vixarelimab demonstrated dose-dependent improvements in itch severity and skin lesion clearance in patients with moderate to severe prurigo nodularis (PN), according to new results from a phase 2b randomized clinical trial. Res
- Systematic Review Shows BTX Effective for Ischemic Digital Complicationshttps://practicaldermatology.com/news/systematic-review-btx-effective-for-ischemic-digital-complications/2484841/Botulinum toxin (BTX) injections may offer a promising rescue therapy for patients with refractory digital ischemia, ulcers, or gangrene associated with systemic sclerosis and other vasculopathies, according to findings from a systematic review in
- Study: Tirzepatide Shows Early Efficacy in Hidradenitis Suppurativahttps://practicaldermatology.com/news/study-tirzepatide-shows-early-efficacy-in-hidradenitis-suppurativa/2484716/New research shows dual GLP-1/GIP inhibitor tirzepatide, a dual GLP-1/GIP receptor agonist currently approved for type 2 diabetes and obesity, may offer a novel therapeutic option for patients with moderate-to-severe hidradenitis suppurativa (HS), according to a sm
- Study: Itch and Rash Severity Linked to Biologic Use in Eczemahttps://practicaldermatology.com/news/itch-and-rash-severity-linked-to-biologic-use-in-eczema-paper/2484499/Data from a recent pre-proof in the Journal of the American Academy of Dermatology highlights that both itch and lesion severity independently predict biologic treatment initiation in patients with moderate-to-severe atopic de
- From ACAAI: Tapinarof Cream Shows Early Efficacy in Pediatric AD Regardless of Comorbiditieshttps://practicaldermatology.com/news/from-acaai-tapinarof-cream-shows-early-efficacy-in-pediatric-ad-regardless-of-comorbidities/2484383/New data from a pooled sub-analysis of the ADORING 1 and 2 trials show that VTAMA® (tapinarof) cream, 1%, was associated with improvements in children aged 2 to 17 with moderate to severe atopic dermatitis (AD). Results from th
- Red Light PDT with 10% ALA Gel Demonstrates Efficacy for Superficial BCChttps://practicaldermatology.com/news/red-light-pdt-with-10-ala-gel-demonstrates-efficacy-for-superficial-bcc/2484215/
- TrUE-AD4: Opzelura Shows Rapid, Significant Efficacy in Moderate ADhttps://practicaldermatology.com/news/true-ad4-opzelura-shows-rapid-significant-efficacy-in-moderate-ad/2484225/New data from Incyte’s phase 3b TRuE-AD4 trial show that Opzelura® (ruxolitinib cream 1.5%) improved clinical symptoms of moderate atopic dermatitis (AD) in adults with limited response or intolerance to standard thearpy. The